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1168Objectives: Mechanical stapling devices have been established as the mainstay of therapy in the selective
isolation and division of bronchial and vascular structures during anatomic lung resection. Few data are available
regarding the application of energy-based tissue fusion technology during anatomic lung resection. In the pres-
ent study, we evaluated the use of energy-based instruments for the division of the pulmonary arterial and venous
branches during anatomic lung resection.
Methods: Anatomic lung resection (segmentectomy or lobectomy) was performed using energy-based coagu-
lative fusion technology. A low-profile jaw can be used to facilitate dissection in both open and video-assisted
thoracic surgery cases, applying a seal 6 mm wide by 22 mm in length. Two energy applications were applied to
the arterial and venous branches before vessel division.
Results: The bipolar tissue fusion system was used in 211 patients between 2008 and 2010 (104 lobectomies and
107 anatomic segmentectomies). Initially, we used a devicewith a smaller, curved jaw (n¼ 12), producing a 3.3-
to 4.7-cm seal. No arterial dehiscences and 2 partial venous dehiscences that were recognized and controlled
intraoperatively occurred. For the remaining cases, we used a new device with a larger jaw that applied
a seal 6 mmwide by 22mm in length. No arterial or venous dehiscences (vessel size range, 0.4-1.2 cm) occurred.
Conclusions: The bipolar tissue fusion system provided safe and reliable control of pulmonary arterial and
venous branches during anatomic lung resection. The use of energy-based tissue fusion technology represents
a reasonable alternative to mechanical stapling devices during anatomic lung resection. (J Thorac Cardiovasc
Surg 2010;140:1168-73)The standard approach to ligation and division of the
pulmonary vasculature during anatomic lung resection in-
cludes mechanical stapler application using endosurgical
and open stapling devices1 or manual suture ligation and di-
vision.2 Although both approaches have been proved to be
reliable and effective,3 the manual suture ligation technique
can be associated with an increased operative time and the
potential for ligature failure.4,5 The mechanical stapling
approach can also be associated with stapler failure,
resulting in life-threatening bleeding,5 pulmonary paren-
chymal contusion, or staple line dehiscence, leading to he-
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The Journal of Thoracic and Cardiovascular Surmechanical stapling devices require the use of multiple car-
tridge firings to accomplish pulmonary resection and can be
associated with increased operative costs.7
Energy-based coagulative and tissue fusion technology
has been applied effectively in the ligation and division of
vessels and tissues in a wide variety of intra-abdominal
procedures.8 To date, limited data are available regarding
the application of energy-based techniques in the division
of the pulmonary vasculature. Therefore, the goal of the
present investigation was to evaluate the safety and efficacy
of an electrical thermocoagulative device in accomplishing
segmental pulmonary vasculature fusion and division dur-
ing anatomic pulmonary resection. The outcome variables
included success of vessel fusion, operative data, length
of stay, morbidity, and mortality.PATIENTS AND METHODS
Patients
The institutional review board of the University of Pittsburgh approved
the present study (PRO 10010260). Between 2008 and 2010, 211 consec-
utive anatomic lung resections using an energy-based tissue fusion device
for division of the pulmonary vasculature were performed and served as the
patient set for the present analysis. Anatomic segmentectomy was per-
formed in 107 patients (79 video-assisted thoracic surgery [VATS] and
28 open procedures), with the remaining 104 patients undergoing lobec-
tomy (51 VATS and 53 open). The patient demographics and tumor char-
acteristics are listed in Table 1.gery c November 2010
TABLE 1. Patient and tumor characteristics
Patients (n ¼ 211)
Age
Mean 64.8
Range 19-88
Gender 116 F, 95 M
Histology
Adenocarcinoma 79 (37%)
Squamous cell CA 42 (20%)
Large cell CA 9 (4%)
Other lung CA 27 (13%)
Metastatic cancer 24 (12%)
Benign 30 (14%)
Tumor Size
Mean (cm) 2.9
Range (cm) 0.5-14.3
Approach
VATS 130 (62%)
Open 81 (38%)
F, female; M, male.
Abbreviation and Acronym
VATS ¼ video-assisted thoracic surgery
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Anatomic segmentectomy (n¼ 107) and lobectomy (n¼ 104) were per-
formed, as described previously.9 A VATS approach was used in 79 seg-
ments and (74%) 51 lobes (49%), with the VATS approach constituting
62% of all resections. The primary determinants in selecting a patient
for segmentectomy were limited functional status, previous pulmonary re-
section, underlying patient comorbidities, and surgeon judgment regarding
resectability using a segmental approach (small, peripheral lesions con-
fined to a discrete bronchopulmonary segment). Lobar resections were per-
formed in a standard fashion. Anatomic segmentectomies were performed
as follows: right upper lobe (apical, anterior, posterior, or apicoposterior
segments), right middle lobe (medial or lateral segments), right lower
lobe (superior or basilar segments), left upper lobe (upper division or lin-
gular segments), and right lower lobe (superior or basilar segments).
Vascular Fusion and Division
Electrical thermocoagulative fusion of the pulmonary vessels was per-
formed using the LigaSure device (Valley Lab, Boulder, Colo) (Figure 1).
It is currently the only Food and Drug Administration-approved energy
device for division of the thoracic vasculature. This device is fitwith a central
cutting blade between the 2 coagulative surfaces of the instrument, promot-
ing effective coagulative ligation (or sealing) and division of the pulmonary
vessel or parenchyma. The system creates a vessel ligation (seal) by applica-
tion of bipolar electrosurgical radiofrequency energy (coagulation) to vessels
interposed between the jaws of the device.When applied to a vessel or tissue
bundle, the radiofrequency energy reorganizes the collagen and elastin struc-
ture within the tissues using a combination of heat and pressure to achieve
tissue fusion, thereby forming a permanent seal. An advantage of this system
is the creation of sufficient, consistent jaw closure force for reliable, consis-
tent tissue fusion. The microprocessor in the generator monitors the tissue
properties, stops the application of energy, and allows a brief period of cool-
ing before indicating that the seal cycle has been completed.
Two hand-held instruments were used during the present series
(Figure 1). The LigaSure Impact (n ¼ 12) is 18 cm in length with a 14
curved jaw. The seal width measures 3.3 to 4.7 mm. The LigaSure Atlas
(n ¼ 199) instrument measures 20 cm in length, facilitating use in both
open and VATS cases. The low-profile jaw can be used to facilitate dissec-
tion and applies a seal 6 mm wide by 22 mm in length. An insulated layer
minimizes heat transmission to the exterior jaw surfaces, with the thermal
spread typically limited to 2 mm. This device has been approved by the
Food and Drug Administration for fusion and division of lymphatics, tissue
bundles, and pulmonary vasculature up to 7 mm in size.
Two energy applications are typically applied before vessel division.
Both pulmonary arterial and venous branches were divided using this tech-
nique. For pulmonary veins, we found division to be safer by taking the
first-order branches of the vein, instead of the main trunk. Similarly, for ar-
teries, we have generally divided primary pulmonary arteries up to 7 mm
in diameter. For larger vessels, vascular division was achieved at the level
of the first-order branches. We currently do not advocate the use of the
LigaSure device for primary parenchymal division during segmentectomy
and, instead, perform a stapled, extended segmentectomy encompassing
the intersegmental planes with 3.5-mm and 4.5-mm staplers.9
Hospital Course
All patients were monitored carefully in the intensive care unit overnight
and were transferred to the floor the next day. Strict attention was paid to
chest tube outputs, perioperative hemoglobin trends, and serial chest radio-The Journal of Thoracic and Cargraph findings. Chest tube management and discharge planning were indi-
vidualized according to the patient clinical characteristics and surgeon
judgment. Chest tubeswere removedwhen air leaks had ceased anddrainage
had decreased to less than 250 mL/day. The patients were discharged after
chest tube removal and when clinically stable. The discharge criteria were
not influenced by the clinical pathways or the type of surgery performed.
Study End Points
The primary end point for the present analysis was the success of
vascular division using a bipolar tissue fusion device. The secondary end
points included the operative time, estimated blood loss, chest tube dura-
tion, length of stay, morbidity, and mortality.
Follow-up
Perioperative data were collected from the hospital chart, anesthesia,
and operating room records, as well as from the electronic medical record
for each patient. All patients were followed up postoperatively at 2 weeks,
at 4- to 6-month intervals for the first 2 years, and yearly thereafter with
computed tomography scans. The mean follow-up was 11.5 months.
RESULTS
Patient and Tumor Characteristics
The patient and tumor characteristics are summarized in
Table 1. The mean patient age was 64.8 years (range, 19-88
years). Of the 211 patients, 95 were men and 116 were
women. The final pathologic findings demonstrated cancer
in 74%, metastases in 12%, and benign disease in 14%.
The mean lesion size was 2.9 cm. Adenocarcinoma consti-
tuted the most common pathologic subtype of non-small
cell lung cancer (37% of cases), followed by squamous
cell carcinoma (20% of cases). All lobar and segmental
resections were performed successfully using energy-
based vascular division.
Perioperative Outcomes
Initially, we used a device with a smaller, curved jaw (Li-
gaSure Impact; n ¼ 12 cases), which produced a seal of 3.3diovascular Surgery c Volume 140, Number 5 1169
FIGURE 1. LigaSure device handpieces. A, LigaSure Impact. B, Liga-
Sure Atlas.
TABLE 2. Perioperative outcomes
Variable Patients (n ¼ 211)
Operative time (min) 60
Vessels divided
Arteries 476
Veins 229
Vessel size (mm)
Mean 6
Range 0.4–1.2
Vascular dehiscence
Venous 2
Arterial 0
Estimated blood loss (mL) 100
Chest tube duration (d) 5
Length of stay (median) 6
Complications (%) 25.1
Mortality (30-day) 1 (0.5%)
TABLE 3. Complications
Complication type Patients (n ¼ 211)
Cardiac 15 (7.1%)
Atrial fibrillation 14 (6.6%)
Congestive heart failure 1 (0.5%)
Ventricular arrhythmia 1 (0.5%)
Pulmonary 39 (18.5%)
Air leak 12 (5.7%)
Pneumonia 11 (5.2%)
Bronchoscopy 6 (2.8%)
Pneumothorax 4 (1.9%)
Respiratory failure 13 (6.2%)
Empyema 2 (0.9%)
Infectious 13 (6.2%)
Pneumonia 11 (5.2%)
Empyema 2 (0.9%)
Septicemia 2 (0.9%)
Total patients (n) 53 (25.1%)
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venous dehiscences developed that were recognized and
controlled intraoperatively. The pulmonary veins have com-
paratively thinner vessel walls and associated reduced col-
lagen content. The graded diameter of the curved tip did
not seemingly achieve a seal as durable as that achieved
with the thicker pulmonary arterial vessels. Therefore, for
the remaining cases, we used a new device with a larger,
higher pressure jaw that applies a seal 6 mm wide by
22 mm in length (LigaSure Atlas). No arterial or venous de-
hiscences occurred in vessels ranging from 0.4 to 1.2 cm.
The wider seal width (6 mm) appeared to enhance the vas-
cular fusion integrity. Vascular division was successfully
performed on 476 arterial and 229 venous branches without
the need for hemostatic adjuncts (eg, clips or staples) The
mean number of arteries divided was 2.3 per case and the
mean number of veins was 1.1 per case. No cases of delayed
hemorrhage occurred. The median operative time was
60 minutes. The median estimated blood loss was 100 mL
(range, 10-800 mL). The median chest tube duration was
5 days, and the length of stay was 6 days (Table 2). In addi-
tion to a prolonged air leak (defined as a persistent air leak
for>5 days; n ¼ 12, 5.7%), the observed chest tube dura-
tion was influenced by several variables, including transient
air leaks (<5 days), persistent chest tube fluid output, time
spent on the ventilator (positive pressure ventilation), and
lung expansion and space management issues. These data1170 The Journal of Thoracic and Cardiovascular Surare comparable to the perioperative outcomes achieved
with the use of endostaplers.9Morbidity and Mortality
Two patients (1.5%) in the VATS group required conver-
sion to an open incision. No conversions were required sec-
ondary to intraoperative hemorrhage. Complications
occurred in 53 patients (25.1%) and are listed in Table 3.
The most common complication was atrial fibrillation,
which occurred in 14 patients (6.6%). Prolonged air leaks
longer than 5 days (5.7%) and pneumonia (5.2%) were
the most common pulmonary complications. One patient
(0.5%) died perioperatively (30 days) secondary to pneu-
monia with progression to acute respiratory distress syn-
drome. No postoperative complications occurred that
were directly attributable to the use of the LigaSure device.gery c November 2010
FIGURE 2. A, Introduction of LigaSure device by way of thoracoscopic port. B, Application of LigaSure device to anterior and apical arteries of left upper
division. Note, divided superior pulmonary vein contribution to left upper division (black arrow). C, Following closure of jaws, vascular fusion is accom-
plished with 2 energy applications. D, Arterial (white arrows) and venous (black arrow) stumps after fusion and division.
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With the introduction of VATS techniques, the endosta-
pler has become the primary method of dividing both the
pulmonary parenchyma and the vasculature.10,11 The use
of energy-based devices for tissue fusion and division has
gained increased popularity and use in a wide variety of
intra-abdominal procedures. Few data currently exist re-
garding the use of this technology in thoracic applications,
such as the division of the pulmonary vasculature during an-
atomic lung resection. Several energy-based fusion devices
are currently available. Only the LigaSure device has been
approved by the Food and Drug Administration for division
of the intrathoracic vasculature and was, therefore, the de-
vice chosen for the present analysis.
The use of an energy-based device for vascular division
within the thorax has been predicated on the findings of nu-
merous animal studies, as well as a few clinical studies in
humans. In preclinical swine models, the use of the bipolar
electrocoagulation sealing devices has been shown to
achieve a durable burst pressure strength of approximately
300 mm Hg, comparable to the burst pressures generated
by vascular clips and staples, and far in excess of the pres-
sures generated within the pulmonary vasculature.12 In a bo-
vine study testing the burst pressures of 5-mm arterial
vessels treated with 4 different vascular sealing devices,
the LigaSure device had greatest burst pressure (385 mm
Hg) and shortest sealing time (10 seconds).13 Sugi and
colleagues14 extended these studies to an evaluation of theThe Journal of Thoracic and Carfusion and division of the pulmonary vasculature in a live
swine model and found that the LigaSure device safely di-
vided pulmonary vessels<5 mm in size, despite increasing
pulmonary pressures to a challenge pressure of 75 mm Hg.
Lacin and colleagues15 compared the vascular integrity of
divided pulmonary arteries during lobectomy in sheep.
They performed lobectomy in 12 sheep and compared the
integrity of the fused vessels in those undergoing upper lo-
bectomy (n ¼ 6) and lower lobectomy (n ¼ 6). Among the
sheep undergoing lower lobectomy, the vascular dehiscence
rate was 33% for the arteries and 50% for the veins larger
than 9 mm in diameter. No vascular disruption was seen in
the smaller arteries (mean, 5.7 mm) and veins (mean,
4.6 mm) encountered during upper lobectomy. These data
suggested that the LigaSure device could be applied safely
to smaller vessels up to 7 mm in size.15
In humans, the LigaSure device has demonstrated suc-
cess in dividing major splenic, renal, and colonic arteries,
and its use within the abdomen has been well-estab-
lished.16-18 Several small series exploring its application
within the chest have been published. The first case report
of lung resection using the LigaSure was by Shigemura
and colleauges.19 The same group, and others, have studied
the use of bipolar tissue fusion during simple wedge resec-
tion, with excellent results.20-22 Albanese and colleagues23
were the first to report a series of anatomic lung resections
performed in newborns for lesions diagnosed prenatally. In
that series, lobar resection was performed in 14 infants fordiovascular Surgery c Volume 140, Number 5 1171
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tion. No intraoperative or postoperative complications
developed. Meehan and colleagues24 used both the Liga-
Sure and the Gyrus PK device to perform robotic lung resec-
tions in 6 children without adverse events. Santini and
colleagues25 reported their experience in the use of the
LigaSure device during lung resection in 36 patients, divid-
ing vessels up to 7 mm in size. No major perioperative
bleeding and no mortality occurred.
In the present series, the LigaSure vessel fusion technol-
ogy was applied in 211 cases. Although 2 partial venous de-
hiscences were encountered using the LigaSure Impact
handpiece, no vascular dehiscence were encountered using
the LigaSure Atlas device during the division of 476 arteries
and 229 veins ranging in size from 0.4 mm up to 1.2 cm. It is
believed that the uniform, wider jaw and greater sealing
pressure of the LigaSure Atlas achieved a more reliable
seal in this setting. This was particularly true for the thin-
walled pulmonary veins. We also found that 2 applications
of energy before division of the vessel achieved a more se-
cure sealing zone. The partial vascular dehiscences encoun-
tered in the present series were readily controlled with
suture ligation and were not associated with major blood
loss, hemodynamic instability, or subsequent perioperative
complications. These data suggest that the LigaSure Impact
device can be safely and effectively used during vascular di-
vision for both anatomic segmentectomy and lobectomy.
The potential advantages of the bipolar tissue fusion
technology include its ease of use in both open and thoraco-
scopic procedures. The smaller profile jaws are easier to
pass around smaller vessels compared with the more bulky
endostapling instruments. Excellent hemostasis can be
achieved during the course of resection, with no bleeding
typically seen from themargins of the resection. This device
can also be used to develop the fissures and perform simple
wedge resection,26 with minimal thermal spread to the tis-
sues surrounding the sealing line (2-3 mm). Furthermore,
a single hand-held device avoids the use of multiple reload-
able stapler cartridges, thus reducing operative costs. The
LigaSure device is priced at $350. Assuming the use of
1.5 staplers per case ($300 each) and an average stapler car-
tridge cost of $100, the total cost savings of performing the
vascular divisions in 89 lobectomies (average 3.5 vessels/
case) and 122 segmentectomies (average 2.0 vessels per
case) with the LigaSure would be in excess of $75,000 for
the patients treated in the present study. This did not account
for the multiple staple loads used to develop the fissures that
would also be amenable to division with the LigaSure,
potentially increasing the cost savings to more $1000 per
patient. Such measures would further augment the reduced
cost attributed to the VATS approach compared with stan-
dard thoracotomy.27,28
The present study was limited by its retrospective nature,
introducing the possibility of bias in patient selection and1172 The Journal of Thoracic and Cardiovascular Surperioperative management. No comparison groups were
included to enhance the evaluation of the outcomes. The re-
sults of the present study should not be generalized to the
use of any energy-based tissue fusion device during ana-
tomic lung resection. Careful intraoperative decision-
making and postoperative monitoring are required to ensure
optimal patient outcomes.CONCLUSIONS
The use of the LigaSure bipolar tissue fusion system rep-
resents a safe and effective technique for the division of
both pulmonary arteries and veins (ideally 7 mm) during
anatomic lung resection. It can be considered a valid alter-
native to stapling technology in this setting. Although not
specifically assessed in the present analysis, the use of
this device could potentially lead to decreased operative
costs by avoiding the use of the multiple endostapling car-
tridges typically required during anatomic lung resection.
Larger prospective series with long-term results and cost/
benefit analyses are necessary to better define the utility
of this technology during anatomic lung resection.
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Dr Mark J. Krasna (Towson, Md). Very nice, Rod. How did
you measure the vessel size when you talk about estimating the
width, 6 mm, and did you also use this technique to control the
airways during your segmentectomies?
Dr Landreneau. First, that distance is 2 cm from that black
mark distally to the black mark proximally up near the hinge point
of the jaw. So, it was an estimate determined by the relationship of
the vessel size to that 2 cm length on that 1020 device.
We did not use this on the airways.
Dr Todd L. Demmy (Buffalo, NY). I think this is great work,
Rodney. We have been using the LigaSure as well for a number of
years. You have to be careful if you are using the 5-mm device,
becausewith less collagen in the veinwall, it can give away after di-
vision. Thus, I think this is great innovation using the larger device.
One other option I think the audience should know about is that
the same company that makes the LigaSure makes a 3-row stapler.
It is an older standard endovascular stapler, but it has a very small
anvil, and you can pass that through the same type of incision, sta-
ple the proximal end with the 3-row stapler, and then you can use
the LigaSure on the side that is coming out. That is another way to
handle it. I wonder if you have ever tried that.
Dr Landreneau. I have not tried it because of just frustration
with getting the staples involved with the LigaSure device. That
is a problem if you use a combination stapler/LigaSure is that it
will not complete the seal if there is even a small staple inside
the jaw. We have tried to avoid that, but that is a reasonable
method you have described if you can get enough distance be-
tween them.diovascular Surgery c Volume 140, Number 5 1173
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